Title page
Word count: 2762

Title: Chemosensory dysfunctions induced by COVID-19 can persist up to 7 months: A study of over 700 healthcare workers

Authors: Nicholas **Bussière**[1]; Jie **Mei**[1], PhD; Cindy **Lévesque-Boissonneault**[1], MSc; Mathieu **Blais**[2,3], PhD; Sara **Carazo**[4], MD, PhD; Francois **Gros-Louis**[2,3], PhD; Gaston **De Serres**[4], MD, PhD; Nicolas **Dupré**[5,6], MD, MSc, FRCP FAAN; Johannes **Frasnelli**[1], MD

[1] Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

[2] Axe Médecine régénératrice, CHU de Québec–Université Laval, Québec City, QC, Canada

[3] Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada

[4] Institut National de Santé Publique du Québec, Québec City, QC, Canada

[5] Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada

[6] Axe Neurosciences, CHU de Québec–Université Laval, Québec City, QC, Canada

Correspondence to be sent to :

Johannes Frasnelli MD,

Université du Québec à Trois-Rivières,

3351, boul. des Forges, C.P. 500,

Trois-Rivières, QC G9A 5H7 Canada

Email: johannes.a.frasnelli@uqtr.ca

Abstract:

Several studies have revealed either self-reported chemosensory alterations in large groups or objective quantified chemosensory impairments in smaller populations of patients diagnosed with COVID-19. However, due to the great variability in published results regarding COVID-19-induced chemosensory impairments and their follow-up, prognosis for chemosensory functions in patients with such complaints remains unclear. Our objective is to describe the various chemosensory alterations associated with COVID-19 and their prevalence and evolution after infection. A cross-sectional study of 704 healthcare workers with a RT-PCR confirmed SARS-CoV-2 infection between 28/2/2020 and 14/6/2020 was conducted 3 to 7 months after onset of symptoms. Data were collected with an online questionnaire. Outcomes included differences in reported chemosensory self-assessment of olfactory, gustatory, and trigeminal functions across time points and Chemosensory Perception Test scores from an easy-to-use at-home self-administered chemosensory test. Among the 704 participants, 593 (84.2%) were women, the mean (SD) age was 42 (12) years, and the questionnaire was answered on average 4.8 (0.8) months after COVID-19. During COVID-19, a decrease in olfactory, gustatory, and trigeminal sensitivities were reported by 81.3%, 81.5% and 48.0% respectively. Three to seven months later, reduced sensitivity was still reported by 52.0%, 41.9% and 23.3% respectively. Chemosensory Perception Test scores indicate that 19.5% of participants had objective olfactory impairment. These data suggest a significant proportion of COVID-19 cases have persistent chemosensory impairments at 3 to 7 months after their infection but the majority of those who had completely lost their olfactory, gustatory, and trigeminal sensitivity have improved.

Keywords: COVID-19, anosmia, parosmia, long-term, taste, trigeminal system

42 **Introduction:**

43 Coronavirus disease-2019 (COVID-19) is an ongoing major public health challenge. Olfactory
44 dysfunction (OD) is a specific symptom that may affect approximately 60% of patients suffering
45 from COVID-19[1-3], and is now considered as a stronger indicator of COVID-19 than fever,
46 cough and shortness of breath[4].

47 Investigation of the long-term effects of COVID-19 on chemosensory function is
48 hindered by the recent onset of the pandemic and other challenges: First, many studies include a
49 relatively small number of participants[5, 6] or participants with severe forms of COVID-19[7, 8].
50 Secondly, many studies include participants with an unclear diagnosis of COVID-19, and/or self-
51 diagnosis [9, 10]. Lastly, while individuals with anosmia can usually evaluate their olfactory
52 function with accuracy[11], this self-assessment is often challenging for individuals with
53 intermediate forms of OD (e.g., hyposmia)[12].

54 OD can be quantitative or qualitative. Quantitative OD defines a reduction of olfactory
55 sensitivity which can be either a complete (*anosmia*) or a partial (*hyposmia*) loss of olfactory
56 function[13]. Qualitative OD describes an altered perception of olfactory stimuli, such as *parosmia*,
57 the perception of qualitatively altered smells, or *phantosmia*, the perception of a smell in the
58 absence of an objective odorant[13, 14]. Overall, the prevalence of OD in the general population is
59 around 20% [15, 16], and all different forms of OD are associated with reduced quality of life and
60 increased risk of depression and anxiety[17]. In addition to OD, COVID-19 also appears to affect
61 other chemosensory functions, i.e. gustatory and trigeminal perception [9, 18].

62 To comprehensively understand long-term olfactory, gustatory, and trigeminal alterations
63 after COVID-19, we analyzed questionnaire responses from a cohort of healthcare workers
64 infected with SARS-CoV-2 during the first wave of the pandemic (February - June 2020). We

65 also developed a Chemosensory Perception Test (CPT), a formal test employing common
66 household odorants and tastants, to enable accessible yet accurate self-evaluation of
67 chemosensory functions.

68 **Materials and Methods:**

69

70 **Participants**

71 Participants were recruited from a Quebec healthcare worker cohort who have had SARS-CoV-2
72 infection between 28/2/2020 and 14/6/2020. They were part of a study from the Institut National
73 de Santé Publique du Québec and had agreed to be contacted for other research projects[19].
74 Inclusion criteria were (1) RT-PCR confirmed COVID-19 (2) above 18 years of age, (3) French
75 or English speakers, (4) completed the online questionnaire, and (5) did not report of other
76 respiratory diseases (bacterial or viral infection, or/and allergies with rhinorrhea) within 2 weeks
77 prior to questionnaire completion or chronic sinusitis (Figure 1).

78 This study was reviewed and approved by the research ethics board of the CHU
79 de Québec – Université Laval (MP-20-2021-5228) and all protocols were reviewed by an
80 independent Scientific Review Committee. This study also complies with the Declaration of
81 Helsinki for Medical Research Involving Human Subjects. All participants provided an online
82 informed consent prior to participation. The study received funding from the Fonds de recherche
83 du Québec-Santé. No compensation or incentive was offered for participation. Data were
84 collected from August 11 to October 29, 2020. Up to four attempts were made to reach by email
85 potential participants. At the time of data collection, participants were 3-7 months after the onset
86 of COVID-19 symptoms.

87

88 **Online questionnaire:**

89 All participants were asked to complete an online questionnaire which was adapted from the core
90 questionnaire of the Global Consortium on Chemosensory Research[9].

91 Demographic information: In the first part of the questionnaire, demographic information
92 was collected from all participants. Participants were then instructed to provide medical history
93 and indicate the presence of specific COVID-19 symptoms (Figure 2).
94 Chemosensory self-assessment: Participants were asked to self-evaluate and report their
95 olfactory, gustatory, and trigeminal sensitivity using a 10-point visual analog scale (VAS; Figure
96 2) for three timepoints: (1) before SARS-CoV-2 infection, (2) during SARS-CoV-2 infection and
97 (3) at questionnaire completion. Further, information on the presence of parosmia or phantosmia
98 following the infection[20] and alterations in the 5 tastes (sweet, salty, sour, bitter, umami) was
99 collected.
100 Chemosensory Perception Test (CPT): Items commonly found in North American
101 households were used to assess participants' olfactory and gustatory functions, as odor intensity
102 is the best single predictor to classify individuals with normosmia[21]. Participants had to smell
103 three substances (peanut butter, jam/jelly, and coffee) and rate odor intensity on a 10-point VAS
104 (0: no smell at all; 10: very strong smell). We obtained olfactory scores by averaging these
105 ratings. Pilot data on a total of 93 participants show these scores to accurately detect OD when
106 compared to the Sniffin' Sticks (cut-off score: 6/10; sensitivity: 0.765; specificity: 0.895;
107 Supplement 3). Participants were asked to prepare saline and sweet water by dissolving
108 respectively a teaspoon of salt or 3 teaspoons of sugar in a cup (250 mL) of lukewarm water.
109 Then, they were asked to taste saline and sweet water and to rate taste intensities on a 10-point
110 VAS. We obtained gustatory scores by averaging these ratings.
111
112 **Statistical Analyses:**

A Python script (Python 3.7.5, Python Software Foundation, https://www.python.org) was used to process raw questionnaire data and to calculate the number of participants reporting COVID-19 symptoms, chronic conditions and recent respiratory illnesses. Processed data were analyzed and visualized with SPSS 26.0 (Armonk, NY: IBM Corp), GraphPad Prism 8.3.1 (GraphPad Prism Software, San Diego, CA) and Raincloud plots[22].

Parametric (ANOVA) or non-parametric (Friedman) tests were chosen depending on whether normality assumption was fulfilled. To evaluate the effects of COVID-19 on *modality* (olfactory, gustatory, and trigeminal) and *time* (prior to, during and after COVID-19 infection), for *gender* (women, men), repeated measures (rm) ANOVA with age as a covariate were computed. To disentangle interactions, separate rmANOVA were carried out for individual modalities and timepoints with the same factors. Greenhouse-Geisser corrections were used for sphericity and Tukey's multiple comparisons test were used for post-hoc comparisons. Friedman's test was followed by Dunn's post-hoc test to correct for multiple comparisons. To assess the correlation between self-reported olfactory, gustatory, and trigeminal abilities and results of the CPT, Pearson correlation coefficient or Spearman's rank correlation coefficient was used. For all statistical tests, alpha was set at 0.05. All results are expressed as mean (SD) unless otherwise specified.

130 **Results:**

131

132 **Characteristics of participants:**

133 A total of 704 healthcare workers (593 (84.2%) women, mean age of 42.0 (SD:11.7, range 18 –
134 70) years were included. The questionnaire was completed on average 4.8 (SD: 0.8, range 3-7)
135 months after symptoms onset. COVID-19 symptoms reported by the 704 participants are listed in
136 Table 1.

137

138 **Quantitative disorders:**

139 Before COVID-19, average self-reported score was 9.0 (1.6), 9.2 (1.3) and 8.9 (1.9) of 10 for
140 olfaction, gustation and trigeminal function, respectively. Among participants, 0.9%, 0.7% and
141 1.8% respectively reported an absence of olfaction, gustation and trigeminal function (score 0;
142 Figure 3). During COVID-19, average self-reported score was 2.6 (3.6) for olfaction, 3.4 (3.6)
143 for gustation, and 7.0 (3.0) for trigeminal sensitivity. In the 704 participants, 51.1%, 33.5% and
144 5.7% reported absence of olfaction, gustation and trigeminal function. At time of questionnaire
145 completion, mean scores were 7.4 (2.5), 8.0 (2.2) and 8.5 (2.2) for olfaction, gustation and
146 trigeminal function respectively and absence of chemical senses was reported respectively by
147 1.4%, 0.7% and 2.3%.

148 Compared to the baseline chemosensory functions before COVID-19, 572 (81.3%), 574
149 (81.5) and 338 (48.0%) reported lower olfactory, gustatory, and trigeminal sensitivity during
150 COVID-19. Olfactory and gustatory dysfunction were present in similar proportions ($\chi^2(2,$
151 $N=704) =0.02$, $P=.891$) and were different to trigeminal (olfaction: $\chi^2(2, N=704) = 174.81$
152 $P<.001$; gustation: $\chi^2(2, N=704) = 174.56$ $P<.001$). Three to seven months after the infection,

366 (52.0%), 295 (41.9%), 164 (23.3%) reported lower olfactory, gustatory, and trigeminal sensitivity compared to before COVID-19 (Table 2). These proportions were significantly different between all three chemosensory systems ($\chi^2(2, N=704) = 123.46$, $P<.001$). Overall, there were significant effects of *modality* ($F(2,1402)=42.83$, $P<.001$, $\eta_p^2=0.058$; olfactory<gustatory<trigeminal; all $P<.001$), *time* ($F(2,1402)=118.47$, $P<.001$, $\eta_p^2=0.145$; during<after<before; all $P<.001$), and *gender* ($F(1,701)=5.52$, $P=0.019$, $\eta_p^2=0.008$; women<men) and significant interactions between these factors (*modality*time, modality*time*gender*; all $P<.001$) on chemosensory self-evaluation. To disentangle these interactions, we analyzed data separately per chemosensory modality and time points.

<u>Chemosensory modality</u>: With regards to <u>olfactory</u> function, significant main effects of *time* ($F(2,1402)=165.07$, $P<.001$ $\eta_p^2=0.191$; during<after<before; all $P<.001$; Figure 3A), *age* ($F(1,701)=4.42$, $P=.012$, $\eta_p^2=0.009$) and *gender* ($F(1,701)=4.42$, $P=.036$, $\eta_p^2=0.006$; women < men) were revealed. In addition, we observed significant interactions of *time*age* ($F(2,1402)=23.39$, $P<.001$, $\eta_p^2=0.032$) and *time*gender* ($F(2, 1402)=21.69$, $P<0.001$, $\eta_p^2=0.030$). With regards to <u>gustatory</u> function, we observed significant main effects of *time* ($F(2,1402)=102.97$, $P<.001$, $\eta_p^2=0.128$; during<after<before; all $P<.001$; Figure 3B) and *gender* ($F(1, 701)=9.80$, $P=.002$, $\eta_p^2=0.014$; women<men), but no effect of *age*. We also observed significant interactions of *time*age* ($F(2, 1402))=5.97$, $P=.005$, $\eta_p^2=0.008$) and *time*gender* ($F(2, 1402))=20.02$, $P<.001$, $\eta_p^2=0.028$).

With regards to <u>trigeminal</u> function, we observed significant main effects of *time* ($F(2,1402)=3.91$, $P=.020$, $\eta_p^2=0.006$; during<after<before; all $P<.001$; Figure 3C), and age ($(1,701)=5.08$, $P=.025$, $\eta_p^2=0.007$) but no effect of *gender*. We also identified significant

interactions of *time*age* (F(2, 1402)=4.70, *P*=.016, η_p^2=0.007) and *time*gender* (F(2, 1402)=4.50, *P*=.019, η_p^2=0.006).

Time point: With regards to chemosensory function before infection, we observed a significant effect of *gender* (F(1,701)=8.52, *P*=.004, η_p^2=0.012; men < women), but not of *modality*, *age* nor interactions. During COVID-19, we observed a significant effects of *modality* (F(2, 1402)=96.714, *P*<.001, η_p^2=0.121; olfaction<gustation<trigeminal; all *P*<.001), *gender* (F(1, 701)=21.98, *P*<.001, η_p^2=0.030; women<men), and age (F(1, 701)=4.74, *P*=.030, η_p^2=0.007). Further, we found significant interactions *modality*age* (F(2, 1402)=24.185, *P*<.001, η_p^2=0.033) and *modality*gender* (F(2, 1402)=6.76, *P*=.002, η_p^2=0.010). Finally, after infection, we observed a significant effect of *modality* (F(2, 1402)=9.91, *P*<.001, η_p^2=0.014; olfaction<gustation<trigeminal; all *P*<.015), but not of *gender* or *age*, nor any interaction.

Compared to baseline (before infection), changes in chemosensory function were correlated for all modalities during infection (olfaction-gustation: ρ=0.69; gustation-trigeminal: ρ=0.43; olfaction-trigeminal: ρ=0.33; all *P*<.001, Figure 4 A-C) and after infection (olfaction-gustation: ρ=0.69; gustation-trigeminal: ρ=0.40; olfaction-trigeminal: ρ=0.36; all *P*<.001, Figure 4 D-F).

Qualitative disorders:

Among included participants, 78 (11.1%) reported parosmia, 73 (10.4%) experienced phantosmia and/or 82 (11.6%) had waxing and waning of olfaction following infection. In addition, 42 (6.0%) claimed that they experienced other forms of OD (hyposmia to specific substances, hyperosmia, parosmia only at high concentrations or slow identification times).

Furthermore, 335 (47.6%) participants reported changes to perception of sweet, 338 (48.0%) salty, 293 (41.6%) sour, 309 (43.9%) bitter and 281 (39.9%) umami. A total of 275 (39.1%) participants reported alterations in all 5 tastes.

Chemosensory Perception Test:

Among the 704 participants, 137 (19.5%) had a CPT score suggestive of OD. Mean CPT scores were lower for olfaction than gustation (7.84 (1.78) vs 8.42 (2.31); Z=8.193, *P*<.001). Neither *age* nor *gender* had an effect on CPT scores. CPT scores correlated with self-reported chemosensory abilities at testing time (olfaction: ρ=0.67; gustation: ρ=0.51; *P*<.001 for both).

208 **Discussion:**

209 This study reports chemosensory dysfunction 3 to 7 months following SARS-CoV-2 infection in
210 a large cohort of RT-PCR-confirmed healthcare workers. In addition to confirming the now well-
211 established detrimental effect of acute COVID-19 on all three chemosensory systems (olfactory,
212 gustatory, trigeminal), our major findings are: (1) the detrimental effect of COVID-19 lasts
213 beyond the acute phase after the infection, half of those affected indicated that olfactory function
214 had not returned to the baseline levels 3 to 7 months later, while 20% of infected participants
215 reported scores in a formal test that are consistent with the presentation of hyposmia/anosmia; (2)
216 approximately 10% of the patients exhibit parosmia and/or phantosmia; (3) women are more
217 heavily affected than men.

218 We observed chemosensory dysfunction in the acute phase of COVID-19, which was
219 most pronounced for olfactory function, but less so for gustatory function and even less for
220 trigeminal function. The proportion of participants describing OD and GD in the acute phase of
221 COVID-19 in this study was comparable to earlier studies[23]. Nevertheless, on average 4.8
222 months after infection and thus well after the acute phase, approximately 50% and 40% of
223 patients reported persistent alterations in olfactory and gustatory sensitivity, respectively; these
224 numbers are higher than what has been reported[24, 25].

225 We found a moderate-to-strong correlation between self-reported olfactory and gustatory
226 changes, which were stronger than with self-reported trigeminal changes. This could be due to
227 similar pathophysiological alterations in the olfactory and gustatory systems and their differences
228 from that of the trigeminal system. Knowing that the general population often mixes up retro-
229 olfaction (perceiving odors from the substances in the mouth traveling posteriorly and rostrally
230 to the olfactory epithelium) with taste, an alternative explanation would be a misunderstanding of

231 this nuance by participants despite the fact that specific definitions for each modality were
232 given[26 27]. The latter hypothesis is more probable since the correlation between gustatory self-
233 report and CPT gustatory scores using strict gustatory stimuli (salt, sugar) is lower than the
234 correlation between olfactory self-report and CPT olfactory scores.

235 Moreover, approximately 10% reported parosmia and/or phantosmia following SARS-
236 CoV-2 infection. These qualitative smell disorders usually involve unpleasant olfactory
237 sensations (rotten eggs, sewage, smoke). While the exact patho-mechanism of parosmia and
238 phantosmia are still to be elucidated, parosmia is probably linked to altered peripheral
239 input/central processing of olfactory stimuli[28]. Importantly, patients with postviral OD and
240 parosmia exhibit better recovery rates following olfactory training than those without parosmia[29].
241 Follow-ups will determine to what extent parosmia predicts a better outcome.

242 Women's chemical senses were more affected than men by the infection. Women
243 typically have better scores in olfactory testing than men [30]. In turn, women exhibit a higher
244 prevalence and a longer persistence of postviral OD[31, 32], in line with our results. Gender
245 differences could be explained by a multitude of neuroendocrine, social, and cognitive factors[31].
246 This suggests that the burden of COVID-19-related OD is more important for women than for
247 men.

248 Different theories have been proposed to explain the persistence of OD in certain
249 individuals, ranging from olfactory epithelium dysfunction to central nervous system infection [33-
250 35]. Since cells of the olfactory epithelium possess the ability to regenerate, the re-establishment
251 of olfactory function is possible in the context of postinfectious OD [36], as well as in COVID-19-
252 related OD, where 75-85% of the affected individuals recovered olfactory function within 60
253 days [24, 37]. In addition to OD and GD, TD has also been reported in patients with COVID-19 [9, 18].

254 Our study indicates chemosensory dysfunction in 18.9% of participants as measured by the CPT
255 3 to 7 months after infection.

256 Persistent chemosensory dysfunctions may be a sign of chronic central nervous system
257 alterations[38, 39], and there is now evidence that SARS-CoV-2 can infect olfactory sensory
258 neurons in humans[40]. Other viruses, such as the Japanese encephalitis virus, Varicella-Zoster
259 virus, measles virus, human immunodeficiency virus and CoVs, were shown to invade the
260 CNS[41]. Febrile seizures, loss of consciousness, convulsions, ataxia, status epilepticus,
261 encephalitis, myelitis, neuritis and extrapyramidal symptoms are among extra-pulmonary
262 symptoms that have been described[42]. The persistence of postinfectious neurological symptoms
263 may contribute to the development or aggravation of chronic neurological diseases such as
264 Parkinson, multiple sclerosis, or psychiatric outcomes[41, 43-51]. These patients should be followed
265 up to document the development of neurological sequalae.

266 Olfactory and other chemosensory dysfunctions may have detrimental effects. First,
267 affected individuals can expose themselves to harmful substances such as smoke, gas or spoiled
268 food[52, 53]. It may trigger dysfunctional nutritional patterns like increased salt and sugar
269 consumption and anorexia[54, 55]. Individuals with OD also have higher rates of anxiety and
270 depression[17, 56]. Moreover, a functioning olfactory system may be a necessity in some
271 workplaces such as in healthcare, where staff are required to have the ability to detect and
272 qualify the smell of urine, excrement, infected wounds or abnormal smells of breath[57]. Currently,
273 there is no approved therapy for COVID-19-induced OD, although olfactory training has a
274 significant effect on olfactory function according to studies on other viral infections[58-60]. Most
275 importantly, long-term follow-up of these patients will be necessary to assess other signs of
276 neurological damage.

277

278 Limitations

279 Given the cross-sectional design of the study, a recall bias is possible for all self-reported
280 peri-SARS-CoV-2 infection values before or during the SARS-CoV-2 infection due to the 3-to-
281 7-month gap. This study did not control for potential confounding factors like race and level of
282 education. Finally, the CPT requires further validation for its gustatory and trigeminal
283 components, and it relies on substances found in participants' homes, which may lead to
284 variation in test results due to the differences in the brand, quality, or expiration date of
285 substances and consequently, their ability to trigger equal sensorineural responses.

286 **Conclusions:**

287 Nearly two thirds of SARS-CoV-2 infected patients had chemosensory impairments during their
288 infection and despite improvements, impairments persist in more than half of them 3 to 7 months
289 after COVID-19. Quantitative and qualitative olfactory dysfunction as well as persisting
290 gustatory and trigeminal deficits were common in the cohort presented in this study. Given the
291 frequency of these problems and the possible neurological underpinnings of these observations,
292 it will be critical to understand the underlying mechanisms of these chemosensory dysfunctions,
293 their evolution, and possible therapeutic options.

Acknowledgments:

We thank Josiane Rivard for preparing the online questionnaire, Cécilia Tremblay, Émilie Aubry-Lafontaine and Frédérique Roy-Côté for data collection and the validation of the Chemosensory Perception Test, and all study participants and frontline healthcare workers facing the COVID-19 pandemic. This work was supported by Fonds de recherche du Québec – Santé (chercheur boursier junior 2 #283144 to JF). NB and JF had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is the recipient of a tier-2 Canada research Chair. All authors declare no conflict of interest.

302 **References:**

303 1. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or
304 Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA*. 2020;323 (20):2089-
305 2090. doi:10.1001/jama.2020.6771 %J JAMA
306 2. Whitcroft KL, Hummel T. Olfactory Dysfunction in COVID-19: Diagnosis and Management.
307 *JAMA*. 2020;323 (24):2512-2514. doi:10.1001/jama.2020.8391 %J JAMA
308 3. von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-
309 19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. *ACS Chem*
310 *Neurosci*. Oct 7 2020;11(19):2944-2961. doi:10.1021/acschemneuro.0c00460
311 4. Gerkin R, Ohla K, Veldhuizen M, Joseph P, Kelly C, Bakke A, et al. Recent Smell Loss Is the
312 Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chemical Senses*.
313 02/01 2021;46
314 5. Le Bon S-D, Pisarski N, Verbeke J, Prunier L, Cavelier G, Thill M-P, et al. Psychophysical
315 evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort
316 study on 72 patients. *Eur Arch Otorhinolaryngol*. 2020;doi:10.1007/s00405-020-06267-2
317 6. Hintschich CA, Wenzel JJ, Hummel T, Hankir MK, Kühnel T, Vielsmeier V, et al.
318 Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients.
319 *International forum of allergy & rhinology*. 2020;10(9):1105-1107. doi:10.1002/alr.22655
320 7. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell
321 dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;doi:10.1002/alr.22587
322 8. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory
323 Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated
324 Characteristics. *Otolaryngol Head Neck Surg*. 2020;doi:10.1177/0194599820929185
325 9. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More than smell.
326 COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. *medRxiv*.
327 2020:2020.05.04.20090902. doi:10.1101/2020.05.04.20090902
328 10. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia
329 during the COVID-19 pandemic – an observational cohort study. *Journal of Otolaryngology - Head &*
330 *Neck Surgery*. 2020/05/04 2020;49(1):26. doi:10.1186/s40463-020-00423-8
331 11. Lötsch J, Hummel T. Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-
332 Based Assessment of 6000 Patients. *Chem Senses*. Jul 17 2019;44(6):357-364.
333 doi:10.1093/chemse/bjz029
334 12. Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory
335 function. *Chem Senses*. Oct 2003;28(8):691-4. doi:10.1093/chemse/bjg061
336 13. Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. Position paper
337 on olfactory dysfunction. *Rhinology*. Jan 31 2016;56(1):1-30. doi:10.4193/Rhin16.248
338 14. Sjölund S, Larsson M, Olofsson JK, Seubert J, Laukka EJ. Phantom Smells: Prevalence and
339 Correlates in a Population-Based Sample of Older Adults. *Chemical senses*. 2017;42(4):309-318.
340 doi:10.1093/chemse/bjx006
341 15. Yang J, Pinto JM. The Epidemiology of Olfactory Disorders. *Curr Otorhinolaryngol Rep*.
342 2016;4(2):130-141. doi:10.1007/s40136-016-0120-6
343 16. Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction.
344 *Laryngoscope*. Oct 2004;114 (10):1764-9. doi:10.1097/00005537-200410000-00017
345 17. Croy I, Nordin S, Hummel T. Olfactory Disorders and Quality of Life—An Updated Review.
346 *Chemical Senses*. 2014;39(3):185-194. doi:10.1093/chemse/bjt072
347 18. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19
348 and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*. 2020;107 (2):219-233.
349 doi:10.1016/j.neuron.2020.06.032
350 19. Carazo SLD, Villeneuve J, Martin R, Deshaies P, Denis G, , Adib G, Tissot F, Dionne M,
351 De Serres G Characterization and evolution of infection control practices among SARS-CoV-2 infected

352 healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring 2020.
353 *Infect Contr Hospit Epidemiol*. in press 2021;
354 20. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of structured
355 questions in parosmia assessment. *Laryngoscope*. Aug 2010;120 (8):1707-13. doi:10.1002/lary.20955
356 21. Parma V, Hannum ME, O'Leary M, Pellegrino R, Rawson NE, Reed DR, et al. SCENTinel 1.0:
357 development of a rapid test to screen for smell loss. *Chem Senses*. Mar 27
358 2021;doi:10.1093/chemse/bjab012
359 22. Allen M, Poggiali D, Whitaker K, Marshall T, van Langen J, Kievit R. Raincloud plots: a multi-
360 platform tool for robust data visualization [version 2; peer review: 2 approved]. *Wellcome Open*
361 *Research*. 2021;4(63)doi:10.12688/wellcomeopenres.15191.2
362 23. Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, et al. Olfactory and
363 gustatory dysfunction in COVID-19 patients: A meta-analysis study. *Physiol Rep*. Sep 2020;8(18):
364 e14578. doi:10.14814/phy2.14578
365 24. Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence
366 and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients.
367 https://doi.org/10.1111/joim.13209. *Journal of Internal Medicine*. 2021/01/05 2021;n/a (n/a)
368 doi:https://doi.org/10.1111/joim.13209
369 25. Capelli M, Gatti P. Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional
370 recovery after eight months. *J Laryngol Otol*. 2021:1-5. doi:10.1017/S0022215121000670
371 26. Landis BN, Frasnelli J, Reden J, Lacroix JS, Hummel T. Differences Between Orthonasal and
372 Retronasal Olfactory Functions in Patients With Loss of the Sense of Smell. *Archives of Otolaryngology–*
373 *Head & Neck Surgery*. 2005;131 (11):977-981. doi:10.1001/archotol.131.11.977 %J Archives of
374 Otolaryngology–Head & Neck Surgery
375 27. Malaty J, Malaty IA. Smell and taste disorders in primary care. *Am Fam Physician*. Dec 15
376 2013;88(12):852-9.
377 28. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia: An
378 fMRI Study. *ORL J Otorhinolaryngol Relat Spec*. 2019;81(4):185-192. doi:10.1159/000500558
379 29. Liu DT, Sabha M, Damm M, Philpott C, Oleszkiewicz A, Hähner A, et al. Parosmia is Associated
380 with Relevant Olfactory Recovery After Olfactory Training. *Laryngoscope*. Mar 2021;131 (3):618-623.
381 doi:10.1002/lary.29277
382 30. Wang X, Zhang C, Xia X, Yang Y, Zhou C. Effect of gender on odor identification at different
383 life stages: a meta-analysis. *Rhinology*. Oct 1 2019;57(5):322-330. doi:10.4193/Rhin19.005
384 31. Sorokowski P, Karwowski M, Misiak M, Marczak MK, Dziekan M, Hummel T, et al. Sex
385 Differences in Human Olfaction: A Meta-Analysis. Systematic Review. 2019-February-13 2019;10 (242)
386 doi:10.3389/fpsyg.2019.00242
387 32. Liu J, Pinto JM, Yang L, Li L, Sun J, Miao X, et al. Gender difference in Chinese adults with
388 post-viral olfactory disorder: a hospital-based study. *Acta Otolaryngol*. Sep 2016;136 (9):976-81.
389 doi:10.3109/00016489.2016.1172729
390 33. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of
391 an Olfactory Route to Brain Infection. *Neuroscientist*. 2020;doi:10.1177/1073858420956905
392 34. Solomon T. Neurological infection with SARS-CoV-2 — the story so far. *Nature Reviews*
393 *Neurology*. 2021/02/01 2021;17(2):65-66. doi:10.1038/s41582-020-00453-w
394 35. Bilinska K, Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular
395 Mechanism. *ACS Chem Neurosci*. 2020;doi:10.1021/acschemneuro.0c00406
396 36. Cavazzana A, Larsson M, Münch M, Hähner A, Hummel T. Postinfectious olfactory loss: A
397 retrospective study on 791 patients. *Laryngoscope*. Jan 2018;128 (1):10-15. doi:10.1002/lary.26606
398 37. Mullol J, Alobid I, Mariño-Sánchez F, Izquierdo-Domínguez A, Marin C, Klimek L, et al. The
399 Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. *Curr Allergy Asthma*
400 *Rep*. 2020;20(10):61-61. doi:10.1007/s11882-020-00961-1

401 38. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after
402 infection with COVID-19 and other coronaviruses. *Brain, Behavior, and Immunity*. 2020/03/30/
403 2020;doi:https://doi.org/10.1016/j.bbi.2020.03.031
404 39. Gori A, Leone F, Loffredo L, Cinicola BL, Brindisi G, De Castro G, et al. COVID-19-Related
405 Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. *Front Neurol*. 2020;11:956-956.
406 doi:10.3389/fneur.2020.00956
407 40. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal
408 SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat*
409 *Neurosci*. Nov 30 2020;doi:10.1038/s41593-020-00758-5
410 41. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. *Cell Host Microbe*.
411 Apr 17 2013;13(4):379-93. doi:10.1016/j.chom.2013.03.010
412 42. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory
413 Virus Infections. *Front Cell Neurosci*. 2018;12:386. doi:10.3389/fncel.2018.00386
414 43. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J*
415 *Virol*. Oct 2000;74(19):8913-21. doi:10.1128/jvi.74.19.8913-8921.2000
416 44. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of
417 probable Parkinson's disease after SARS-CoV-2 infection. *Lancet Neurol*. Oct 2020;19(10):804-805.
418 doi:10.1016/s1474-4422 (20)30305-7
419 45. Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia M, Cereda PM. Human coronavirus
420 polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. *New Microbiol*.
421 Apr 1997;20(2):105-14.
422 46. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with
423 Parkinson's disease. *Mov Disord*. 1992;7(2):153-8. doi:10.1002/mds.870070210
424 47. Johnson-Lussenburg CM, Zheng Q. Coronavirus and multiple sclerosis: results of a case/control
425 longitudinal serological study. *Adv Exp Med Biol*. 1987;218:421-9. doi:10.1007/978-1-4684-1280-2_51
426 48. Morris JA. Clinical viral infections and multiple sclerosis. *Lancet*. Aug 3 1985;2 (8449):273.
427 doi:10.1016/s0140-6736(85)90318-6
428 49. Murray RS, Brown B, Brian D, Cabirac GF. Detection of coronavirus RNA and antigen in
429 multiple sclerosis brain. *Ann Neurol*. May 1992;31(5):525-33. doi:10.1002/ana.410310511
430 50. Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple
431 sclerosis patients. *Virology*. Nov 1992;191 (1):502-5. doi:10.1016/0042-6822 (92)90220-j
432 51. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric
433 outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.
434 *Lancet Psychiatry*. Apr 1 2021;doi:10.1016/s2215-0366 (21)00084-5
435 52. Schiffman SS. Smell and Taste. In: Birren JE, ed. *Encyclopedia of Gerontology (Second Edition)*.
436 Elsevier; 2007:515-525.
437 53. Gonzales GM, Cook MJ. CHAPTER 13 - DISORDERS OF SMELL AND TASTE. In: Schapira
438 AHV, Byrne E, DiMauro S, et al, eds. *Neurology and Clinical Neuroscience*. Mosby; 2007:171-177.
439 54. Aschenbrenner K, Hummel C, Teszmer K, Krone F, Ishimaru T, Seo HS, et al. The influence of
440 olfactory loss on dietary behaviors. *Laryngoscope*. Jan 2008;118 (1):135-44.
441 doi:10.1097/MLG.0b013e318155a4b9
442 55. Mattes R, Cowart B, Schiavo M, Arnold C, Garrison B, Kare M, et al. Dietary evaluation of
443 patients with smell and/or taste disorders. *The American journal of clinical nutrition*. 03/01 1990;51:233-
444 40. doi:10.1093/ajcn/51.2.233
445 56. Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The Association Between Olfaction and
446 Depression: A Systematic Review. *Chem Senses*. Jul 2016;41(6):479-86. doi:10.1093/chemse/bjw061
447 57. Kelly M. Scent of a patient: an underestimated role in clinical practice? *Br J Gen Pract*. 2012;62
448 (600):378-378. doi:10.3399/bjgp12X652481
449 58. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta-
450 analysis. *Rhinology*. Mar 1 2017;55(1):17-26. doi:10.4193/Rhin16.195

59. Doty RL. Treatments for smell and taste disorders: A critical review. *Handb Clin Neurol*. 2019;164:455-479. doi:10.1016/b978-0-444-63855-7.00025-3

60. Damm M, Pikart LK, Reimann H, Burkert S, Göktas Ö, Haxel B, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. *Laryngoscope*. Apr 2014;124 (4):826-31. doi:10.1002/lary.24340

61. Rumeau C, Nguyen DT, Jankowski R. How to assess olfactory performance with the Sniffin' Sticks test®. *European Annals of Otorhinolaryngology, Head and Neck Diseases*. 2016/06/01/ 2016;133 (3):203-206. doi:https://doi.org/10.1016/j.anorl.2015.08.004

62. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav*. Mar 1984;32(3):489-502. doi:10.1016/0031-9384 (84)90269-5

463 **List of tables:**

464 **Table 1.** COVID-19 symptoms of the 704 participants.

Symptoms at time of SARS-CoV-2 infection	No. (%)
Fever	353 (50.1%)
Dry cough	361 (51.7%)
Cough with mucus	77 (10.9%)
Dyspnea	316 (44.9%)
Chest tightness	201 (28.6%)
Runny nose	226 (32.1%)
Sore throat	330 (46.9%)
Changes in food flavor	471 (66.9%)
Changes in smell	520 (73.9%)
Loss of appetite	323 (45.9%)
Headache	518 (73.6%)
Muscle aches	444 (63.1%)
Fatigue	611 (86.8%)
Diarrhea	259 (36.8%)
Abdominal pain	102 (14.5%)
Nausea	179 (25.4%)

465

466 **Table 2.** Self-reported chemosensory alterations by age group and gender during and 3 to 7

467 months following COVID-19 (n=704).

468

		During acute COVID-19			3-7 months after COVID-19		
		Olfaction	Gustation	Trigeminal	Olfaction	Gustation	Trigeminal
Age	Gender	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
18-29	M (N= 11)	9 (81.8)	9 (81.8)	4 (36.4)	6 (54.5)	5 (45.5)	3 (27.3)
	F (N=115)	106 (92.2)	106 (92.2)	54 (47.0)	68 (59.1)	55 (47.8)	16 (13.9)
30-39	M (N=26)	23 (88.5)	21 (80.8)	12 (46.2)	13 (50.0)	7 (26.9)	4 (15.4)
	F (N=153)	133 (86.9)	129 (84.3)	77 (50.3)	83 (54.2)	63 (41.2)	37 (24.2)
40-49	M (N=33)	23 (69.7)	23 (69.7)	13 (39.4)	12 (36.4)	9 (27.3)	5 (15.2)
	F (N=165)	142 (85.5)	137 (83.0)	83 (50.3)	97 (58.8)	77 (46.7)	42 (25.5)
50-59	M (N=28)	13 (46.4)	14 (50.0)	9 (32.1)	7 (25.0)	7 (25.0)	4 (14.3)
	F (N=128)	100 (78.1)	102 (79.7)	66 (51.6)	62 (48.4)	57 (44.5)	39 (30.5)
60+	M (N=13)	5 (38.5)	6 (46.2)	5 (38.5)	2 (15.4)	1 (7.7)	3 (23.1)
	F (N=32)	19 (59.4)	27 (84.4)	15 (46.9)	16 (50.0)	14 (43.8)	11 (34.4
	Total (N=704)	**572 (81.3)**	**574 (81.5)**	**338 (48.0)**	**366 (52.0)**	**295 (41.9)**	**164 (23.2)**

469 **List of figures:**

470 **Figure 1. Flowchart of participant inclusion/exclusion procedures.** Flowchart of the study

471 design. INSPQ: Institut national de santé publique.



472 **Figure 2. Web-based interface and structure of the online questionnaire**. Left, Self-rating of

473 olfaction and reporting of CPT using VAS through the web-based interface, as viewed by the

474 participant. Right, Sections of the online questionnaire. VAS: visual analog scale.



Consent	
Q1-Q4: personal information	• Year of birth • Place of residence • Gender
Q5-Q10: COVID-related questions	• Diagnosis of COVID-19 • Date of symptom onset • Date of positive COVID-19 test • Stage of COVID-19 • COVID-19 related symptoms • Treatment/medication received
Q11-Q20: medical history and substance use	• Other respiratory diseases in last two weeks • Symptoms associated with respiratory diseases • Treatment received • Usage of cigarette, e-cigarette, marijuana/cannabis • History of other diseases
Q21-Q31: self-reported OD, GD and TD scores	• Self-evaluation of olfactory, gustatory and trigeminal functions • Change in olfaction and gustation
Q32-Q61: Chemosensory Perception Test	• Availability of substances at home • Reporting of smell and/or taste of the substance

Figure 3. Self-reported scores for the chemosensory modalities before, during and after COVID-19 infection (n=704). Raincloud plot representing self-reported scores for olfaction, gustation, and trigeminal function before, during and after COVID-19. Ratings from individual participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, self-reported scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19 and have not fully returned to baseline values 5 months after COVID-19.



482 **Figure 4. Correlations between alterations in chemosensory modalities (n=704).** Red squares,
483 correlations between alterations in olfaction, gustation, and trigeminal functions during COVID-
484 19. Grey hexagons, correlations between alterations in olfaction, gustation, and trigeminal
485 functions after COVID-19. Darker colors indicate higher occurrence.

486
487



Supplementary 1:

Validation of the Chemosensory Perception Test

This study was reviewed and approved by the research ethics board of the Université du Quebec à Trois-Rivières (CER-20-268-08-01.04). All participants provided a verbal or written informed consent prior to participation.

Experiment 1:

Methods

Participants were recruited among previously tested groups. Olfactory testing was performed using the standardized Sniffin' Sticks test at our laboratory from 2016 to 2019. Exclusion criteria was any perceived changes of their sense of smell since previous testing. Participants were distributed into 2 groups based on their Threshold-Discrimination-Identification (TDI) scores. The first group consists of participants with normal olfactory function (normosmia), defined as TDI scores above 30.5[61]. The second group had subjective olfactory dysfunction and equivalent TDI scores. Participants were administered CPT by means of a telephone interview.

Results:

TDI scores in the first group range from 32.5 to 41.5 (N= 19, 9 women and 10 men, age range [60-78]). TDI scores in the second group ranged from 8 to 30.25 (N= 17, 7 women and 10 men, age range [57-77]). CPT scores were positively correlated with the Sniffin' Sticks (ρ=0.837, P<0.001). A cut-off score of 6 at the CPT had a sensitivity of 0.765 and specificity of 0.895.

Experiment 2:

Methods:

Participants were recruited among previously tested groups, participants from this cross-sectional study and in the public via social media. They were administered the University of Pennsylvania

512 Smell Identification Test (UPSIT) (which was sent by mail) and the CPT under direct supervision
513 through videoconferencing. Participants were distributed into 2 groups based on their UPSIT
514 scores with a score equal or less than 33 in males and 34 in females defining hyposmia[62].

515 Results:

516 UPSIT scores in the normosmic group ranged from 34 to 28 (n=29 (21 women), age range [22-
517 73]). The hyposmic group had UPSIT scores ranging from 9 to 34 (n= 28 (21 women), age range:
518 [22-72]). CPT scores were significantly correlated with the UPSIT score (ρ=0.377, P=0.004) in
519 the whole group of participants. We found this correlation to be much stronger in the hyposmic
520 group (ρ=0.702, P<0.001).

521 **Conclusions:**

522 The CPT allows for distinction between normosmia and olfactory dysfunction with high sensitivity
523 and specificity. CPT scores are significantly correlated to UPSIT and Sniffin Sticks scores,
524 especially in a group of individuals with olfactory dysfunction.

525
526